Results 231 to 240 of about 8,375,026 (338)

Immune evasion mechanisms of human papillomavirus: An update

open access: yesInternational Journal of Cancer, 2018
Alina Steinbach, A. Riemer
semanticscholar   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

open access: yesInternational Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype.

open access: bronze, 1991
Peter J. Hurlin   +5 more
openalex   +1 more source

PI3Kγ in Tumour Inflammation: Bridging Immune Response and Cancer Progression—A Mini‐Review

open access: yesImmunology, EarlyView.
Myeloid cell PI3Kγ can be activated by G Protein‐Coupled Receptors or Receptor Tyrosine Kinases. Once activated, PI3Kγ promotes integrin activation as well as Akt and mTOR activation, thereby promoting transcription of immune‐suppressive and pro‐angiogenic factors, such as Arginase, IL‐10, TGFβ and VEGF‐A.
Anghesom Ghebremedhin, Judith A. Varner
wiley   +1 more source

Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects

open access: yesImmunology, EarlyView.
The figure depicts the role of flagellin in immune cells. Flagellin interacts with TLR5, resulting in the formation of homodimers and the recruitment of MyD88, which activates the IκB and MAPK signalling pathways. This results in the activation of NF‐κB and AP‐1, producing TNF‐α, IL‐6, IL‐8, and IL‐12.
Asma Talukder   +4 more
wiley   +1 more source

Human papillomavirus in Bangladesh: Challenges and opportunities for prevention. [PDF]

open access: yesGynecol Oncol Rep
Salauddin M   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy